Van Diest Capital’s Gilead Sciences GILD Stock Holding History

Van Diest Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,052	Closed	-$286K	–	191
2026 Q1	$286K	Buy	+2,052	New	+$287K	0.23%	130

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Van Diest Capital's GILD Position: Q2 2026 in Review

Van Diest Capital sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 2,052 shares — an estimated $286K sold.

Van Diest Capital first reported a position in GILD in Q1 2026 and held it in 1 quarter. The position peaked at $286K in Q1 2026. 2,272 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Van Diest Capital reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
Van Diest Capital sold 2,052 Gilead Sciences shares in Q2 2026, an estimated $286K.
Van Diest Capital first reported a position in Gilead Sciences in Q1 2026 and held it in 1 quarter.
Van Diest Capital's Gilead Sciences position peaked at $286K in Q1 2026.
2,272 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Van Diest Capital's 13F filing for Q2 2026, filed 4 Aug 2026.